Eli Lilly unveils new pill that lowers blood sugar, weight for Type 2 diabetics

Eli Lillys new pill can lower blood sugar, weight in people with Type 2 diabetes
Eli Lilly's new pill can lower blood sugar, weight in people with Type 2 diabetes

Eli Lilly has announced a daily pill that lowers blood sugar levels and promotes weight loss in individuals suffering from Type 2 diabetes.

The experimental pill, known as Orforglipron, is a GLP-1 drug announced on Wednesday, April 16 2025, the similar class of medicine as the best diabetes and weight loss drugs Ozempic, Wegovy and Mounjaro.

“Everybody knows GLP-1s now, and they’re sort of famous as injectable peptide drugs, but we’ve engineered this now into a new kind of molecule that can be taken as a pill form,” Lilly’s chief scientific officer Dr. Dan Skovronsky stated.

If the drug gets approved, Lilly’s medicine would be the second oral GLP-1 drug accessible in the U.S. The first, Rybelsus, produced by Novo Nordisk, contains semaglutide, the active ingredient in Ozempic and Wegovy.

Lilly stated that the drug is currently in the phase 3 clinical trial, and its results will be published in a peer-reviewed journal and presented at the American Diabetes Association conference, which is set to occur in June.

In addition, Eli Lilly is conducting research on the results of orforglipron works on weight loss alone in people without Type 2 diabetes.

The daily pill, Orforglipron was found to be effective for weight loss with an average reduction of 9.4% to 14.7% after 36 weeks, according to the findings of phase 2 clinical trial.

Elli Lilly announced on Thursday, April 17 2025, that phase 3 results from the weight loss trial will be available shortly. 

Furthermore, the company revealed plans to submit the medicine to the Food and Drug Administration as a weight loss treatment by the end of 2025.

However, in 2026, the company plans to apply for approval as a diabetes treatment.  

Related
Read more : Health

New Covid strain takes over UK with unique symptoms

New Covid strain takes over UK with unique symptoms
Stratus consists of two strains, XFG and XFG.2, which constitute up to 30% of cases across the UK

THESE common meds do not cause inflammatory bowel disease, study

THESE common meds do not cause inflammatory bowel disease, study
Medicines including NSAIDs like aspirin and ibuprofen, ACE inhibitors, aren’t linked to a higher risk of microscopic colitis

Juice, smoothies and soft drinks can dehydrate you in hot weather, say experts

Juice, smoothies and soft drinks can dehydrate you in hot weather, say experts
Alcohol should also be avoided in hot weather as it causes the body to lose water which often leads to dehydration

Excessive screen time linked to delayed learning in children, study

Excessive screen time linked to delayed learning in children, study
Experts warn too much screen time may hinder language development in young children

Chickpeas show surprising power to cut cholesterol levels in new study

Chickpeas show surprising power to cut cholesterol levels in new study
Those who ate chickpeas everyday showed a major improvement in their cholesterol levels

Air pollution fuels lung cancer in non-smokers, study

Air pollution fuels lung cancer in non-smokers, study
Air Pollution could drive lung cancer mutations in people with little to no history of smoking

15-minute workouts to rapidly lose weight

15-minute workouts to rapidly lose weight
Discover a few effective 15-minute workouts that are scientifically proven to rapidly help reduce fat

Measles outbreak spreads to Kentucky as US case tally reaches 1,267 this year

Measles outbreak spreads to Kentucky as US case tally reaches 1,267 this year
Health officials urge all parents to have their children vaccinated to ensure protection from measles